BLRX : Summary for BioLineRx Ltd. - Yahoo Finance

U.S. Markets closed

BioLine Rx Ltd (BLRX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.26-0.01 (-0.78%)
At close: 4:00PM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.27
Open1.36
Bid1.27 x 500
Ask1.32 x 12300
Day's Range1.20 - 1.35
52 Week Range0.83 - 1.42
Volume1,058,125
Avg. Volume323,565
Market Cap77.52M
Beta-0.13
PE Ratio (TTM)-4.62
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire12 days ago

    BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14

    BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer, David Malek, will present a company update at the 2016 BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 10:30 am EST. The conference will be held at the Waldorf Astoria Hotel in New York. A live webcast of the presentation will be available on BioLineRx's website.

  • BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
    Zackslast month

    BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda

    BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.

  • PR Newswirelast month

    BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer

    TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is part of a research collaboration between MSD and MD Anderson Cancer Center. The open-label, single center, single-arm Phase 2a study aims to evaluate the potential of BL-8040 in combination with KEYTRUDA in pancreatic cancer and focuses on the mechanism-of-action by which both drugs might synergize.